Home / Business and Economy / Lilly Buys Ventyx for $1.2B, Eyes New Drug Pipeline
Lilly Buys Ventyx for $1.2B, Eyes New Drug Pipeline
8 Jan
Summary
- Eli Lilly acquired Ventyx Biosciences for $1.2 billion cash.
- The deal aims to expand Lilly's portfolio beyond diabetes drugs.
- Ventyx develops treatments for inflammatory bowel diseases.
Eli Lilly has agreed to acquire Ventyx Biosciences for $1.2 billion in cash, signaling a significant expansion of its drug development pipeline. This transaction marks Lilly's latest endeavor to diversify its offerings beyond its current blockbuster diabetes and weight-loss treatments.
The acquisition includes Ventyx's portfolio of investigational drugs, notably oral therapies aimed at treating inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. One of Ventyx's drugs is also undergoing mid-stage trials for a cardiovascular condition associated with obesity.
This move follows a highly successful year for Lilly, which saw its market value surpass $1 trillion, driven by the immense sales of its GLP-1 drugs, Mounjaro and Zepbound. The acquisition of Ventyx is poised to strengthen Lilly's position in the pharmaceutical market.
